- Piper Jaffray is positive on Vertex Pharma (NASDAQ:VRTX) taking their tgt to $58 from $42. Firm notes they have taken a closer look at the HCV market, as they believe investors will begin shifting to a commercial focus in the next several quarters, after data from ongoing trials satisfy outstanding clinical uncertainties. After a closer look, the firm believes their prior telaprevir estimates were overly conservative, particularly on the numbers of new patients seeking treatment. Firm's new U.S. and worldwide telaprevir sales estimates are $2.3b and $4.0b (from 1.5b; $2.5b) in 2012.
Preliminary end of treatment data from the ongoing Phase 2 PROVE-1 trial expected in the next few weeks represents a near-term positive catalyst.
Notablecalls: Expect VRTX stock to be flying today. I can easily see 2 pts worth of upside from last close. VRTX is one of biotech's darlings and will most likely be acquired at some point.
Preliminary end of treatment data from the ongoing Phase 2 PROVE-1 trial expected in the next few weeks represents a near-term positive catalyst.
Notablecalls: Expect VRTX stock to be flying today. I can easily see 2 pts worth of upside from last close. VRTX is one of biotech's darlings and will most likely be acquired at some point.
Any thoughts on Dell after formal investigation by SEC announced?
ReplyDelete